Updated progression-free survival data for AstraZeneca's lung cancer candidate AZD9291 has put the drug firmly on course for filing in the first half of this year.Updated results from the ongoing AURA trial... Read more
The search for a new treatment for the progressive neurodegenerative disease ALS has turned to an existing epilepsy drug marketed by GlaxoSmithKline (GSK).New treatments for the disease are desperately needed,... Read more
A phase 3 trial of Pfizer's breast cancer therapy Ibrance has been stopped early after a clear benefit on progression-free survival was seen compared to control.The PALOMA-3 study of recently-approved Ibrance (palbociclib)... Read more
AstraZeneca's biologics arm MedImmune is to research yet another combination of immuno-oncology treatments, as it vies to join the leaders in this cutting-edge therapy area.The firm has unveiled a collaboration... Read more
Latest Press Releases from the Global Pharma Showcase
Arthur G. Cook (ZS Associates) publishes 2nd Edition with Gower
The eagerly awaited second edition of Arthur G. Cook's Forecasting for the Pharmaceutical Industry is now available from Gower.
Forecasting for the Pharmaceutical Industry is a definitive guide for forecasters as well as the multitude of decision makers and executives who rely on forecasts in their decision making.
In virtually every decision, a pharmaceutical executive considers some type of forecast. This process of predicting the future is crucial to many aspects of the company - from next month's production schedule, to market estimates for drugs in the next decade. The pharmaceutical forecaster needs to strike a delicate balance between over-engineering the forecast - including rafts of data and complex ‘black box’ equations that few stakeholders understand and even fewer buy into - and an overly simplistic approach that relies too heavily on anecdotal information and opinion. Arthur G. Cook's highly pragmatic guide explains the basis of a successful balanced forecast for products in development as well as currently marketed products. He explores the pharmaceutical forecasting process; the varied tools and methods for new product and in-market forecasting; how they can be used to communicate market dynamics to the various stakeholders; and the strengths and weaknesses of different forecast approaches.The text is liberally illustrated with tables, diagrams and examples.The final extended case study provides the reader with an opportunity to test out their knowledge.
The second edition has been updated throughout and includes a brand new chapter focusing on specialized topics such as forecasting for orphan drugs and biosimilars.
Arthur G. Cook is a Principal with ZS Associates, a management consulting firm specializing in the pharmaceutical industry. Previously he was Director of Global Forecasting for Syntex Pharmaceuticals. Art has been involved in pharmaceutical forecasting for over 30 years, has worked with many major pharmaceutical companies on their forecasting processes, and has created forecasts for over 150 therapy areas. He has written and presented widely on the subject of forecasting, portfolio management, market research, and pricing for the pharmaceutical industry.
For further information about the book's content and to read a sample chapter or to order, please follow this link http://www.gowerpublishing.com/isbn/9781472460110. Our website gives 10% online discount as standard. If you are interested in bulk purchase, please telephone our sales department on +44 (0)1252 736600.
LAUNCH OF UNIQUE COGNITIVE ASSESSMENT TOOL MYCQPRO TO HELP TRANSFORM MENTAL FITNESS OF BRITISH WORK FORCE
Scientifically designed cognitive evaluation programme to boost cognitive health
and help cut £26bn annual cost of mental health issues to business
MyCognition, the UK’s leading provider of cognitive health technologies, today announces the launch of MyCQPro, a unique assessment tool using patent–pending technology, which evaluates cognitive health and allows individuals to monitor their mental wellbeing. The unique combination of psychometric tests in MyCQPro is set to play a disruptive role in reducing the cost of mental ill-health to UK businesses, which currently totals £26bn annually.
An OECD report, released earlier this month, estimates that, at any one time, 1 in 5 individuals of working age suffer from a mental health problem, with 70 million working days lost annually due to poor mental health. The report also calls for a shift in policy to focus on intervention in the workplace, with emphasis on improving toolkits for managers to enable preventative action.
Businesses are increasingly aware that employee’s mental fitness is as important as their physical health and are seeking to introduce effective wellbeing strategies but are struggling to measure their impact: a 2013 survey by a leading international healthcare consultancy found that only 36% of employers globally are able to measure effectively the outcomes of their health programs.
MyCQPro addresses this evaluation issue and allows individuals to identify their cognitive strengths and assess their progress in improving their cognitive health. Following initial soft launch trials, MyCognition is already working in the financial services sector to meet this wellbeing challenge, and is also in talks with a variety of blue-chip professional services businesses.
MyCQProcan be used by all businesses to address a range of areas including:
·Stress resilience for staff, to enhance retention and productivity;
·Absenteeism and medical claims, through regular cognitive assessment and timely interventions, which strengthen mental coping mechanisms;
·Team cohesion, by identifying the right cognitive mix, and improving performance when integrated with cognitive training;
·Improved leadership, by identifying areas that need strengthening and harnessing cognitive training to give managers the best chance for success
MyCQPro can be carried out from any computer or iPad, is self-administered and only takes 15-minutes. It is a unique cognitive evaluation tool, which maps an individual’s strengths in the five core cognitive domains, which together make up over 90% of our mental activity: working memory, episodic memory, attention, executive function and psychomotor speed. MyCQPro quantifies the extent of cognitive improvement, whether this is as a result of taking one of MyCognition’s training programmes or due to other interventions.
MyCQPro is based on validated and respected tests in the field of neuroscience refined over 200-years of research into the human brain. This unique cognitive evaluation tool, as well as MyCognition’s other products, has been developed in partnership with world-class institutions including the University of Cambridge and Amsterdam Medical Centre, and results from its trials have been endorsed by the Federation of European Neuroscience Societies (FENS).
Research in neuroscience has shown strong links between cognitive domains, such as working memory and executive function, with problem solving ability and strategic planning respectively, both key areas for business. Enhanced executive function can help management more effectively execute non-routine activities, such as mergers and acquisitions and strategic reviews. Firms can also use MyCQPro to help create more cohesive working teams with the right cognitive balance between more creative and more process, delivery driven individuals.
MyCQPro,and MyCognition’s stimulating and interactive training programmes developed with BAFTA-award winning company Preloaded, provide a unique mix of assessment and training in the workplace. This can deliver tangible benefits for businesses, as the programme allows employees to exercise areas in need of development and consolidate existing strengths, which improves stress resilience and strengthens mental coping mechanisms.
This helps to address presenteeism, lost productivity due to employees attending work while suffering from illness, often due to mental health issues. Combating presenteeism was cited in an established global survey of employers as the main motivation for European employers to improve their wellbeing strategies. In the UK, official figures from the Parliamentary Office for Science and Technology put the cost to companies of reduced productivity due solely to mental ill-health at over £15bn each year.
Businesses are increasingly recognising that they need a holistic Employee Value Proposition, covering both mental and physical health – an emphasis that is becoming clearer in employee benefit packages that are starting to include alternative health elements to help limit the damage caused by mental health issues. MyCQPro is a unique new addition to such packages, providing companies and employees with actionable information about their cognitive health and, when combined with MyCognition’s training programmes, gives businesses a validated method to improve the mental wellbeing of their workforce.
Duncan Knight, CEO of MyCognition, commented:
“Businesses are increasingly aware that their employees’ mental fitness is as important as their physical health. Improving cognitive health is vital to enhancing workplace wellbeing and MyCQPro can be a key part of a company’s Employee Value Proposition and holistic wellbeing strategy. In conjunction with MyCognition’s training programmes, it could also help British businesses tackle the £26bn bill they are paying due to employee mental wellbeing issues. Improving employees’ cognitive functions, such as working memory, episodic memory, attention and executive function, decreases stress in employees, reduces absenteeism and helps boost productivity.”
The discount expires this Friday for CreateHealth's Customer Experience (CX) in Health Summit, May 12 London.
On May12th CreateHealth.io will define a clear methodology and share proven tactics used to develop customer centric services that improve patient outcomes.
Here's a snap shot: · Learn to support customers across multiple touch points to drive behaviour change and product ROI. You will learn how making small changes to language, images and functionality (based on customer feedback) will increase engagement to your services and improve email open rates.
· Speakers include:
Rod Willmott,CIO, LV Martin Bellingham, Head of Customer Insight, AXA Andrew Hancock, Head of Customer Services & Revenue Management, EDF Energy Marc Barlow, Head of Global Strategic Marketing, GE Healthcare Alan How, Head of Devices and Digital. Health Commercial Excellence and Business Intelligence Department, Merck Serono Rachel Jones, Global Publications Manager, Pharmacist, AstraZeneca
· Join 100 pharma colleagues + CX leaders from outside Healthcare. With attendees already registered from GSK, Pfizer, Merck, AZ, Sanofi, GP's, European payers, IDF, RBS, AXA, GE...
Secure your discount of £200 & register for only £595 by clicking here:http://createhealth.io/cx/register/
Media Contact: Kate Eversole Director, Marketing firstname.lastname@example.org | +44 (0) 779 6844 655 | createhealth.io
Have you been tasked with developing services that improve patient value?Most pharma CEOs cite the patient voice as their biggest challenge, take Joseph Jimenez’s (CEO Novartis) recent statement in the...
Have you been tasked with developing services that improve patient value?
Most pharma CEOs cite the patient voice as their biggest challenge, take Joseph Jimenez’s (CEO Novartis) recent statement in the New York Times ‘we HAVE to create more patient-centricity and customer focus.' But this requires a change in thinking.
The Customer Experience (CX) in Health Summit, May 12 London lays out a clear methodology and shares proven tactics used to develop customer centric services that improve patient outcomes. Including:
· How GSK, Pfizer and Merck are feeding patient voice, customer insight and point of value into their service strategies for user uplift. · RBS, AXA & EDF will apply their CX frameworks to pharma patient services so you leave with proven methodologies to replicate and build on. · How to use CX tactics to achieve quick wins. Make small changes to language, images and functionality (based on patient feedback) to increase engagement to your services.
You can see the full brochure which drills down in to each session here: http://bit.ly/1CdR4q8 With attendees from GSK, Pfizer, Merck, AZ Sanofi, GP’s, European payers, Travelodge, Barclays...
The early bird discount expires this Friday. Join 100 pharma, save £200 & register for only £595 click here: http://createhealth.io/cx/register/
Farrow and Jones Breathe New Life Into PM Society as Preparations Begin for 30th PM Society Awards in 2016
30 March 2015
Farrow and Jones Breathe New Life Into PM Society
as Preparations Begin for 30th PM Society Awards in 2016
The PM Society has more than doubled its core Committee with the appointment of nine brand and marketing specialists from pharmaceutical companies and 11 senior players from service industries and media[i], as it gears up to celebrate 30 years of its iconic PM Society Awards in 2016.
Under Co-Chairs, Rachel Farrow and Carwyn Jones[ii], who took over in 2014, key focus areas for the Society have been identified as PriMe training and education, Patient engagement, NHS Partnerships and Market Access and the Digital interest group. The PM Society Awards and Digital Media Awards will continue as a platform for recognising and promoting excellence in pharmaceutical marketing.
In addition, two new appointments to the Executive Committee are Jonathan Dancer, Managing Director, Redbow Consulting Group, who will be co-lead on PriMe training with Eamon O’Brien and Colin Williams, Chief Marketing Officer, PharmiWeb Solutions, who will support on digital activities.
In another significant change the Digital Media Awards will move from its traditional autumn slot to take place in the Spring, with the next ceremony planned for April 2016.
“Co-Chair Carwyn Jones comments: “The new Executive and Committee members have been hand-picked for their special interest in one or more key focus areas and a commitment to driving forward initiatives that meet the PM Society’s objective to educate, recognise excellence and share best practice in pharmaceutical marketing.
“2015 will see us bedding in the team and gearing up for a raft of new activities in 2016, kicking off with the 30th PM Society Awards in January. It really is a very exciting time in the history of the Society,” Jones concludes.
Rachel Farrow, Co-Chair comments: “The PM Society is a unique not-for-profit organisation for the UK pharmaceutical industry offering recognition and training to promote excellence in healthcare marketing. Importantly, it recognises all the marketing channels – traditional and new – and looks for integration as it promotes excellence and offers training for individuals at all levels of learning. Our expanded committee has the breadth of expertise to embrace this diversity.”
The PM Society
The PM Society is a not-for-profit organisation, which was founded over 35 years ago as the Pharmaceutical Marketing Society. Today, it has 2120 active members from over 230 companies and drives marketing excellence and education across the life sciences sector through a variety of channels, including the PriMemodular training programme developed for the industry by the industry.
Communications & Patient Relations Lead – Neuroscience and Cardio Metabolic
Novartis Pharmaceuticals Ltd
Founder & Managing Director
Senior Brand Manager
IS Project Manager, Digital Marketing Solutions
Science & Health Communications Consultant
General Manager UK & Ireland
Sales & Marketing Manager, Nordic Countries
Head of Marketing
Daiichi Sankyo UK Ltd
[ii] Rachel Farrow has been on the PM Society Committee for nine years, is a former Vice-Chair and also Chairs the PM Society Digital Media Awards She has worked in the healthcare communications industry for 22 years, managing several agencies, and is currently an independent consultant.
Carwyn Jones is Managing Director at the Earthworks, a healthcare communications agency which is part of the OPEN Health group. Carwyn has been on the PM Society Committee for four years, and is the Digital Lead for the Society, running the popular free Digital Breakfast live webinars.